Dendreon Corp, Seattle, WA 98101, USA.
Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004.
Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response to prostate cancer that prolongs the overall survival of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC). The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented. The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed.
Sipuleucel-T 是一种自体细胞免疫疗法，旨在刺激对前列腺癌的免疫反应，延长无症状或有轻微症状的转移性去势抵抗性前列腺癌（CRPC）男性的总生存期。本文介绍了 III 期研究的临床开发计划和主要疗效、安全性及免疫反应结果，并讨论了 sipuleucel-T 在晚期前列腺癌治疗模式中的融入以及未来的研究方向。
